Following a strategic adjustment to its share capital structure, China's leading online recruitment platform Kanzhun Limited sees sustained bullish sentiment from Wall Street, with a majority of analysts maintaining Buy ratings and forecasting significant upside.
Newly released federal data confirms Texas led all states in job creation last year, setting new historic highs for total employment, workforce size, and nonfarm jobs in December, even as regional disparities persist.
While several stocks have posted impressive gains recently, not all momentum stories are built to last. We analyze one company with durable advantages and two where recent rallies may warrant skepticism.
A strategic report warns that recent tariff hikes could significantly increase clothing costs for American shoppers unless brands rapidly diversify production to a network of partner nations.
With its stock near 52-week highs, Western Digital prepares to unveil its AI-driven storage roadmap at a pivotal New York event, seeking to transition its narrative from cyclical recovery to structural growth.
In uncertain markets, low-volatility stocks offer comfort but may cap upside potential. We analyze one steady performer and two stocks where stability may signal stagnation, helping investors balance risk and reward.
Amidst a market rally driven by a handful of tech giants, certain volatile stocks present outsized risks. We examine three names where valuation concerns and sector headwinds warrant a cautious approach.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Despite a 19.8% stock surge over six months, a closer look at TreeHouse Foods reveals troubling trends in sales volume, profitability, and capital efficiency, prompting a cautious stance from analysts.
Shares of semiconductor materials supplier Entegris have surged nearly 56% in six months, but analysts warn of stretched valuations, slowing growth forecasts, and weak cash generation, suggesting investors may want to look elsewhere for value.
Medical device maker ResMed (RMD) reported fourth-quarter revenue of $1.42 billion, an 11% year-over-year increase that surpassed Wall Street forecasts. Non-GAAP earnings per share reached $2.81, also topping analyst expectations.
Ameriprise Financial (NYSE: AMP) reported robust fourth-quarter results for 2025, surpassing revenue expectations with a 13.1% year-over-year sales increase to $5.05 billion. Adjusted earnings per share of $10.83 also came in ahead of analyst forecasts.
Honeywell International posts a robust Q4 with record orders and backlog, while announcing an accelerated timeline to spin off its core Aerospace business as a standalone public company by late 2026, a move set to redefine its investment profile.
LVMH's wine and spirits arm, led by Hennessy, faces a sharp profit decline amid weak U.S. and Chinese demand, while Rémy Cointreau reports a modest rebound in Cognac sales, highlighting a divided market outlook.
Heineken launches a global marketing initiative celebrating shared passions in sports and music, aiming to foster real-world connections amid declining U.S. sales and a competitive import beer market.
Despite a six-month rally fueled by strong quarterly results, analysts point to sluggish long-term sales growth, weak cash flow, and declining returns on capital as reasons for caution, suggesting investors look elsewhere for opportunity.
Insurance broker Arthur J. Gallagher raises its quarterly dividend, rewarding shareholders even as it continues to pursue an active mergers and acquisitions pipeline, signaling confidence in its dual strategy of capital returns and growth.
Fresh from its spin-off, GE Vernova is finalizing a deal to acquire transformer maker Prolec GE, a strategic move to bolster its electrification portfolio and capitalize on surging global demand for grid infrastructure and power equipment.
Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
